D. Boral Capital Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $2.00 price target on the stock. D. Boral Capital’s price objective would indicate a potential upside of 276.65% from the company’s current price.

A number of other research analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, February 11th. Maxim Group decreased their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, January 10th.

Lineage Cell Therapeutics Price Performance

Shares of LCTX opened at $0.53 on Tuesday. The company has a 50 day simple moving average of $0.60. Lineage Cell Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.61. The firm has a market cap of $117.04 million, a price-to-earnings ratio of -4.43 and a beta of 1.21.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. acquired a new position in shares of Lineage Cell Therapeutics during the 4th quarter worth about $1,984,000. Renaissance Technologies LLC increased its position in Lineage Cell Therapeutics by 1,058.3% during the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock worth $1,147,000 after buying an additional 2,085,972 shares during the last quarter. DAFNA Capital Management LLC raised its stake in Lineage Cell Therapeutics by 85.9% in the fourth quarter. DAFNA Capital Management LLC now owns 2,511,374 shares of the company’s stock valued at $1,262,000 after buying an additional 1,160,666 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in Lineage Cell Therapeutics in the fourth quarter valued at approximately $519,000. Finally, Raffles Associates LP lifted its position in shares of Lineage Cell Therapeutics by 21.8% in the fourth quarter. Raffles Associates LP now owns 5,492,088 shares of the company’s stock valued at $2,760,000 after buying an additional 984,307 shares during the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.